Stock in focus: Bayer celebrates stock exchange mathematics that shareholders should know
After a costly poison pill acquired a good decade ago, there is a lot of good news from the life science group. But it's still a long way to old record highs.
Bayer's stock has seen a significant surge, with a 100% increase over the past 12 months, making it the strongest performer in the Dax and Euro Stoxx 50. The company's stock has nearly tripled since early 2025. Bayer has recently received approval from the US FDA for its stroke treatment, Asundexian, and has raised its annual targets after reporting a net profit of €5.2 billion in the first nine months.
The company is also making progress in resolving lawsuits related to its acquisition of Monsanto, and 16 out of 21 analysts currently recommend buying the stock.
Written by urgent.news from Handelsblatt's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
